Drug Approval | March 21, 2022
Zydus receives PAS approval for Mycophenolate Mofetil
The drug is indicated for use in combination with other drugs
The drug is indicated for use in combination with other drugs
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Nebivolol is used alone or together with other medicines to treat high blood pressure
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
It signals Cordis' renewed investment in innovation
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
Subscribe To Our Newsletter & Stay Updated
